Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 74% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 13.6% — below-average profitability
- Revenue growing at 12% annually
Quest Diagnostics Incorporated (DGX) is a Healthcare company operating in Services-Medical Laboratories, listed on the NYSE , with a market capitalisation of $21.9 billion . Key value metrics: P/E ratio 22.5, P/B ratio 3.05, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Quest Diagnostics Incorporated — Fundamental Analysis Summary
Quest Diagnostics Incorporated (DGX) is currently trading 74% above its Graham Number of $114.04, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 22.5x.
On financial health, DGX shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 13.6% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.79.
StockPik's composite Value Score for DGX is 56/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
DGX reports a moderate gross margin of 33.3% (sector average: 33.5%) and a solid operating margin of 14.0%.
DGX shows revenue growing at 12% year-over-year, with earnings growing at 14%.
DGX pays a modest dividend yield of 1.6%.